O'Brien, S. Et Al. 2016. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. The Lancet Oncology , vol.17, no.10 , 1409-1418.

O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., ... Österborg, A.(2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. The Lancet Oncology , vol.17, no.10, 1409-1418.

O'Brien, Susan Et Al. "Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study," The Lancet Oncology , vol.17, no.10, 1409-1418, 2016

O'Brien, Susan Et Al. "Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study." The Lancet Oncology , vol.17, no.10, pp.1409-1418, 2016

O'Brien, S. Et Al. (2016) . "Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study." The Lancet Oncology , vol.17, no.10, pp.1409-1418.

@article{article, author={Susan O'Brien Et Al. }, title={Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study}, journal={The Lancet Oncology}, year=2016, pages={1409-1418} }